Literature DB >> 2743745

Hypotension induced by central hypovolaemia and hypoxaemia.

L B Rowell1, J R Blackmon.   

Abstract

Our question was whether the reduced orthostatic tolerance that accompanies hypoxaemia in some (not all) subjects might be associated with an abnormally large release of adrenaline. Eight normal young men were exposed to lower body negative pressure (LBNP) at -30 to -40 mmHg while breathing air or 10% O2 in N2. Four subjects developed hypotension and bradycardia whenever LBNP was applied during hypoxaemia; four showed a rise in heart rate and stable blood pressure. During normoxia plasma adrenaline concentration did not rise during LBNP in any subject, nor during hypoxaemia plus LBNP in the subjects who remained normotensive. In the four men whose heart rates and blood pressures fell during LBNP with hypoxaemia, adrenaline rose markedly, reaching 200-1600 pg ml-1. All subjects showed similar elevations in noradrenaline concentration during LBNP in both normoxia and hypoxaemia. The results suggest that reduced tolerance to central hypovolaemia during hypoxaemia could stem from known vasomotor and cardiac effects attending high plasma concentrations of adrenaline.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743745     DOI: 10.1111/j.1475-097x.1989.tb00979.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  12 in total

1.  Impact of environmental stressors on tolerance to hemorrhage in humans.

Authors:  Craig G Crandall; Caroline A Rickards; Blair D Johnson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-12-05       Impact factor: 3.619

2.  Systemic hypoxia and vasoconstrictor responsiveness in exercising human muscle.

Authors:  Brad W Wilkins; William G Schrage; Zhong Liu; Kellie C Hancock; Michael J Joyner
Journal:  J Appl Physiol (1985)       Date:  2006-06-29

3.  Effects of regional phentolamine on hypoxic vasodilatation in healthy humans.

Authors:  C J Weisbrod; C T Minson; M J Joyner; J R Halliwill
Journal:  J Physiol       Date:  2001-12-01       Impact factor: 5.182

4.  Short-term hypoxic vasodilation in vivo is mediated by bioactive nitric oxide metabolites, rather than free nitric oxide derived from haemoglobin-mediated nitrite reduction.

Authors:  Michele Umbrello; Alex Dyson; Bernardo Bollen Pinto; Bernadette O Fernandez; Verena Simon; Martin Feelisch; Mervyn Singer
Journal:  J Physiol       Date:  2014-01-06       Impact factor: 5.182

5.  Failure of systemic hypoxia to blunt alpha-adrenergic vasoconstriction in the human forearm.

Authors:  Frank A Dinenno; Michael J Joyner; John R Halliwill
Journal:  J Physiol       Date:  2003-05-02       Impact factor: 5.182

Review 6.  Blood pressure regulation X: what happens when the muscle pump is lost? Post-exercise hypotension and syncope.

Authors:  John R Halliwill; Dylan C Sieck; Steven A Romero; Tahisha M Buck; Matthew R Ely
Journal:  Eur J Appl Physiol       Date:  2013-11-07       Impact factor: 3.078

7.  Naloxone-provoked vaso-vagal response to head-up tilt in men.

Authors:  P Madsen; M Klokker; H L Olesen; N H Secher
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

8.  Exercise intensity-dependent contribution of beta-adrenergic receptor-mediated vasodilatation in hypoxic humans.

Authors:  Brad W Wilkins; Tasha L Pike; Elizabeth A Martin; Timothy B Curry; Maile L Ceridon; Michael J Joyner
Journal:  J Physiol       Date:  2007-11-29       Impact factor: 5.182

9.  Effect of acute hypoxemia on cerebral blood flow velocity control during lower body negative pressure.

Authors:  Noud van Helmond; Blair D Johnson; Walter W Holbein; Humphrey G Petersen-Jones; Ronée E Harvey; Sushant M Ranadive; Jill N Barnes; Timothy B Curry; Victor A Convertino; Michael J Joyner
Journal:  Physiol Rep       Date:  2018-02

10.  Impact of Resistance Exercise under Hypoxia on Postexercise Hemodynamics in Healthy Young Males.

Authors:  Masahiro Horiuchi; Arisa Ni-I-Nou; Mitsuhiro Miyazaki; Daisuke Ando; Katsuhiro Koyama
Journal:  Int J Hypertens       Date:  2018-07-26       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.